Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2016 | May. 11, 2016 | |
Document And Entity Information | ||
Entity Registrant Name | Imprimis Pharmaceuticals, Inc. | |
Entity Central Index Key | 1,360,214 | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2016 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Smaller Reporting Company | |
Entity Common Stock, Shares Outstanding | 13,305,678 | |
Trading Symbol | IMMY | |
Document Fiscal Period Focus | Q1 | |
Document Fiscal Year Focus | 2,016 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2016 | Dec. 31, 2015 |
Current assets | ||
Cash and cash equivalents | $ 11,821 | $ 2,685 |
Restricted short-term investments | 150 | 150 |
Accounts receivable, net | 943 | 840 |
Inventories | 1,233 | 1,412 |
Prepaid expenses and other current assets | 779 | 786 |
Total current assets | 14,926 | 5,873 |
Intangible assets, net | 3,100 | 3,135 |
Goodwill | 2,466 | 2,466 |
Furniture and equipment, net | 4,814 | 2,657 |
TOTAL ASSETS | 25,306 | 14,131 |
Current liabilities | ||
Accounts payable and accrued expenses | 4,253 | 3,407 |
Accrued payroll and related liabilities | 667 | 1,200 |
Deferred revenue and customer deposits | 50 | 65 |
Current portion of deferred acquisition obligation and accrued interest | 202 | 198 |
Current portion of contingent acquisition obligation | 483 | 483 |
Current portion of capital lease obligations | 15 | 21 |
Total current liabilities | $ 5,670 | 5,374 |
Capital lease obligations, net of current portion | 1 | |
Deferred acquisition obligation, net of current portion | $ 206 | 258 |
Accrued expenses, net of current portion | 500 | 500 |
Deferred tax liability | 1,047 | 1,047 |
Notes payable and paid-in-kind interest, net of unamoritzed debt discount | ||
Note payable and paid-in-kind interest, net of unamortized debt discount | 8,495 | $ 8,336 |
Convertible note payable, net of unamortized debt discount | 604 | |
TOTAL LIABILITIES | 16,522 | $ 15,516 |
STOCKHOLDERS' EQUITY (DEFICIT) | ||
Common stock, $0.001 par value, 90,000,000 shares authorized, 13,105,678 and 9,755,678 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively | 13 | 10 |
Additional paid-in capital | 71,031 | 56,369 |
Accumulated deficit | (62,260) | (57,764) |
TOTAL STOCKHOLDERS' EQUITY (DEFICIT) | 8,784 | (1,385) |
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | $ 25,306 | $ 14,131 |
Condensed Consolidated Balance3
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares | Mar. 31, 2016 | Dec. 31, 2015 |
Statement of Financial Position [Abstract] | ||
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 90,000,000 | 90,000,000 |
Common stock, shares issued | 13,105,678 | 9,755,678 |
Common stock, shares outstanding | 13,105,678 | 9,755,678 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2016 | Mar. 31, 2015 | |
Revenues: | ||
Sales, net | $ 4,381 | $ 1,562 |
License revenues | 1 | |
Total revenues | $ 4,381 | 1,563 |
Cost of sales | (2,249) | (1,007) |
Gross profit | 2,132 | 556 |
Operating expenses: | ||
Selling and marketing | 1,900 | 1,012 |
General and administrative | 3,940 | 2,480 |
Research and development | 46 | 181 |
Total operating expenses | 5,886 | 3,673 |
Loss from operations | (3,754) | (3,117) |
Other income (expense): | ||
Interest expense, net | (629) | $ (7) |
Change in fair value of derivative liabilities | $ (113) | |
Other income | $ 31 | |
Total other income (expense), net | $ (742) | 24 |
Net loss | $ (4,496) | $ (3,093) |
Basic and diluted net loss per share of common stock | $ (0.43) | $ (0.33) |
Weighted average number of shares of common stock outstanding, basic and diluted | 10,407,430 | 9,337,275 |
Condensed Consolidated Stateme5
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2016 | Mar. 31, 2015 | |
CASH FLOWS FROM OPERATING ACTIVITIES | ||
Net loss | $ (4,496) | $ (3,093) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization of furniture and equipment | 83 | 44 |
Amortization of intangible assets | 91 | $ 82 |
Amortization of debt discount | 262 | |
Paid-in-kind added to principal of note payable | $ 51 | |
Non-cash gain on contingent acquisition obligations | $ (31) | |
Change in fair value of derivative liabilities | $ 113 | |
Stock-based compensation | 1,064 | $ 658 |
Changes in assets and liabilities, net of effects from acquisitions: | ||
Accounts receivable | (103) | 44 |
Inventories | 179 | (106) |
Prepaid expenses and other current assets | 7 | (97) |
Accounts payable and accrued expenses | 996 | 104 |
Accrued payroll and related liabilities | (533) | 105 |
Deferred revenue and customer deposits | (15) | 15 |
NET CASH USED IN OPERATING ACTIVITIES | $ (2,301) | (2,275) |
CASH FLOWS FROM INVESTING ACTIVITIES | ||
Purchase of Park Compounding, net of cash | $ (3,005) | |
Investment in patent and trademark assets | $ (56) | |
Purchases of furniture and equipment | (2,367) | $ (28) |
NET CASH USED IN INVESTING ACTIVITIES | (2,423) | (3,033) |
CASH FLOWS FROM FINANCING ACTIVITIES | ||
Payments on capital lease obligations | (7) | $ (7) |
Net proceeds from public equity offering | 11,088 | |
Payments on Park deferred acquisition obligation | (48) | |
Proceeds from convertible note payable, net of issuance costs and fees | 2,772 | |
Net proceeds from exercise of warrants and stock options | $ 55 | $ 77 |
Payments for deferred offering costs | (75) | |
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES | $ 13,860 | (5) |
NET CHANGE IN CASH AND CASH EQUIVALENTS | 9,136 | (5,313) |
CASH AND CASH EQUIVALENTS, beginning of period | 2,685 | 8,211 |
CASH AND CASH EQUIVALENTS, end of period | 11,821 | 2,898 |
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||
Cash paid for income taxes | 9 | 1 |
Cash paid for interest | 291 | $ 2 |
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES: | ||
Fair value of embedded conversion feature recorded as debt discount and derivative liability | 2,322 | |
Reclassification of the fair value of the embedded conversion feature derivative liability to additional paid-in capital upon closing of the public equity offering | 2,646 | |
Reclassification of the fair value of the LSAF additional paid-in capital to derivative liability | 675 | |
Reclassification of the fair value of the LSAF derivative liability to additional paid-in capital upon closing of the public equity financing | $ 464 | |
Issuance of common stock and fair value of deferred acquisition obligations related to the purchase of Park Compounding | $ 966 | |
Issuance of stock options for consulting services included in accounts payable and accrued expenses | $ 23 | $ 39 |
Purchase of furniture and equipment included in accounts payable and accrued expenses | $ 1,148 |
Description of Business and Bas
Description of Business and Basis of Presentation | 3 Months Ended |
Mar. 31, 2016 | |
Accounting Policies [Abstract] | |
Description of Business and Basis of Presentation | NOTE 1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Company and Background Imprimis Pharmaceuticals, Inc. (together with its subsidiaries, unless the context indicates or otherwise requires, the Company or Imprimis) is a national leader in the development, production and dispensing of novel compounded pharmaceuticals. The Companys two business programs, Imprimis Cares Custom Compounding Choice Basis of Presentation Imprimis has prepared the accompanying unaudited condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for audited financial statements. In the opinion of management, all adjustments (consisting of only normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016 or for any other period. For further information, refer to the Companys audited consolidated financial statements and footnotes thereto included in the Companys Annual Report on Form 10-K for the year ended December 31, 2015. The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2016 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The following represents an update for the three months ended March 31, 2016 to the significant accounting policies described in the Companys Annual Report on Form 10-K for the year ended December 31, 2015. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management are, among others, allowance for doubtful accounts and contractual adjustments, realizability of inventories, valuation of deferred taxes, goodwill and intangible assets, recoverability of long-lived assets and goodwill, valuation of contingent acquisition obligations and deferred acquisition obligations, valuation of notes payable and derivative liabilities, and valuation of stock-based compensation issued to employees and non-employees. Actual results could differ from those estimates. Liquidity The Company has incurred significant operating losses and negative cash flows from operations since its inception. The Company incurred net losses of $4,496 and $3,093 for the three months ended March 31, 2016 and 2015, respectively, and had an accumulated deficit of $62,260 and $57,764 as of March 31, 2016 and December 31, 2015, respectively. In addition, the Company used cash in operating activities of $2,301 and $2,275 for the three months ended March 31, 2016 and 2015, respectively. While there is no assurance, the Company believes its existing cash resources and restricted investments of approximately $11,971 at March 31, 2016, will be sufficient to sustain the Companys planned level of operations for at least the next twelve months. However, estimates of operating expenses and working capital requirements could be incorrect, and the Company could use its cash resources faster than anticipated. Further, some or all of the ongoing or planned activities may not be successful and could result in further losses. The Company may seek to increase liquidity and capital resources by one or more measures, to the extent necessary. These measures may include, but are not limited to, the following: obtaining financing through the issuance of equity, debt, or convertible securities; and working to increase revenue growth through pharmacy sales. There is no guarantee that the Company will be able to obtain capital when needed on terms it deems as acceptable, or at all. Concentrations of Credit Risk The Company places its cash with financial institutions deemed by management to be of high credit quality. The Federal Deposit Insurance Corporation (FDIC) provides basic deposit coverage with limits up to $250 per owner. At March 31, 2016, the Company had approximately $11,300 in cash deposits in excess of FDIC limits. Accounts Receivable Accounts receivable are stated net of allowances for doubtful accounts and contractual adjustments. The accounts receivable balance primarily includes amounts due from customers the Company has invoiced or from third-party providers (e.g., insurance companies and governmental agencies), but for which payment has not been received. Charges to bad debt are based on both historical write-offs and specifically identified receivables. Contractual adjustments are determined by the amount expected to be collected from third-party providers. Accounts receivable are presented net of allowances for doubtful accounts and contractual adjustments in the amount of $180 as of March 31, 2016 and December 31, 2015. Revenue Recognition and Deferred Revenue The Company recognizes revenues when all of the following criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. The Companys revenues consist of sales of certain of the Companys proprietary compounded drug formulations and non-proprietary formulations and products. Product Revenues Determination of criteria (3) and (4) is based on managements judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Estimated returns and allowances and other adjustments are provided for in the same period during which the related sales are recorded. The Company will defer any revenues received for a product that has not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered and no refund will be required. License Revenues License arrangements may consist of non-refundable upfront license fees, data transfer fees, research reimbursement payments, exclusive license rights to patented or patent pending compounds, technology access fees, and various performance or sales milestones. These arrangements can be multiple element arrangements. Non-refundable fees that are not contingent on any future performance by the Company and require no consequential continuing involvement on the part of the Company are recognized as revenue when the license term commences and the licensed data, technology, compounded drug preparation and/or other deliverable is delivered. Such deliverables may include physical quantities of compounded drug preparations, design of the compounded drug preparations and structure-activity relationships, the conceptual framework and mechanism of action, and rights to the patents or patent applications for such compounded drug preparations. The Company defers recognition of non-refundable fees if it has continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee and that are separate and independent of the Companys performance under the other elements of the arrangement. In addition, if the Companys continued involvement is required, through research and development services that are related to its proprietary know-how and expertise of the delivered technology or can only be performed by the Company, then such non-refundable fees are deferred and recognized over the period of continuing involvement. Guaranteed minimum annual royalties are recognized on a straight-line basis over the applicable term. Debt Issuance Costs and Debt Discount Debt issuance costs and the debt discount are recorded net of notes payable in the condensed consolidated balance sheets. Amortization expense of debt issuance costs and the debt discount is calculated using the effective interest method over the term of the debt and is recorded in interest expense in the accompanying condensed consolidated statements of operations. Fair Value Measurements Fair value measurements are determined based on the assumptions that market participants would use in pricing an asset or liability. GAAP establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The established fair value hierarchy prioritizes the use of inputs used in valuation methodologies into the following three levels: ● Level 1: Applies to assets or liabilities for which there are quoted prices (unadjusted) for identical assets or liabilities in active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure fair value whenever available. ● Level 2: Applies to assets or liabilities for which there are significant other observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. ● Level 3: Applies to assets or liabilities for which there are significant unobservable inputs that reflect a reporting entitys own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, Level 3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method. At March 31, 2016 and December 31, 2015, the Company did not have any financial assets or liabilities that are measured on a recurring basis. At March 31, 2016 and December 31, 2015, the Companys financial instruments included cash and cash equivalents, restricted short-term investments, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, customer deposits, deferred acquisition obligations, notes payable and capital leases. The carrying amount of these financial instruments, except for deferred acquisition obligations and notes payable, approximates fair value due to the short-term maturities of these instruments. The Companys restricted short-term investments are carried at amortized cost, which approximates fair value. Based on borrowing rates currently available to the Company, the carrying values of the deferred acquisition obligations and notes payable, approximate their respective fair values. Derivative Instruments The Company accounts for free-standing derivative instruments and hybrid instruments that contain embedded derivative features as either assets or liabilities in the condensed consolidated balance sheets and are measured at fair value with gains or losses recognized in earnings. Embedded derivatives that are not clearly and closely related to the host contract are bifurcated and are recognized at fair value with changes in fair value recognized as either a gain or loss in earnings. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models, giving consideration to all of the rights and obligations of each instrument. The Company estimates the fair value of derivative instruments and hybrid instruments using various techniques (and combinations thereof) that are considered to be consistent with the objective of measuring fair value. In selecting the appropriate technique, the Company considers, among other factors, the nature of the instrument, the market risks that it embodies and the expected means of settlement. The Company generally uses the Black-Scholes-Merton option pricing model, adjusted for the effect of dilution, because it embodies all of the requisite assumptions (including trading volatility, estimated terms, dilution and risk-free rates) necessary to fair value these instruments. Estimating the fair value of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. Increases in the trading price of the Companys common stock and increases in fair value during a given financial quarter result in the application of non-cash derivative expense. Conversely, decreases in the trading price of the Companys common stock and decreases in fair value during a given financial quarter would result in the application of non-cash derivative income. Third Party Billing and Collection Agreements In connection with its acquisition of South Coast Specialty Compounding, Inc. D/B/A Park Compounding (Park), the Company entered into a billing and collection agreement with a third party to assist in the billing and collection of workers compensation claims. Under the terms of the agreement, the Company is obligated to pay a fixed fee to the third party equal to 55% of the amounts billed and collected under the workers compensation claims. The Company accrues for such fees in accounts payable and accrued expenses in the accompanying condensed consolidated balance sheets. Total billing and collection management expense under this agreement for the three months ended March 31, 2016 and 2015 were $15 and $6, respectively, and is included in selling and marketing expenses in the accompanying condensed consolidated statements of operations. The amounts due under the agreement as of March 31, 2016 and December 31, 2015 was $59 and $81, respectively. Stock-Based Compensation All stock-based payments to employees, directors and consultants, including grants of stock options, warrants, restricted stock units (RSUs) and restricted stock, are recognized in the condensed consolidated financial statements based upon their estimated fair values. The Company uses the Black-Scholes-Merton option pricing model and Monte Carlo Simulation to estimate the fair value of stock-based awards. The estimated fair value is determined at the date of grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates. The Companys accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows Financial Accounting Standards Board (FASB) guidance. As such, the value of the applicable stock-based compensation is periodically remeasured and income or expense is recognized during the vesting terms of the equity instruments. The measurement date for the estimated fair value of the equity instruments issued is the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendors performance is complete. In the case of equity instruments issued to consultants, the estimated fair value of the equity instrument is primarily recognized over the term of the consulting agreement. According to FASB guidance, an asset acquired in exchange for the issuance of fully vested, nonforfeitable equity instruments should not be presented or classified as an offset to equity on the grantors balance sheet once the equity instrument is granted for accounting purposes. Accordingly, the Company records the estimated fair value of nonforfeitable equity instruments issued for future consulting services as prepaid stock-based consulting expenses in its condensed consolidated balance sheets. Income Taxes The Company accounts for income taxes under the provisions of FASB Accounting Standards Codification (ASC) 740, Income Taxes Basic and Diluted Net Loss per Common Share Basic net loss per common share is computed by dividing net loss attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such as stock options and warrants, outstanding during the period. Basic and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. Common stock equivalents (using the treasury stock or if converted method) from deferred acquisition obligations, stock options, unvested RSUs and warrants were 4,134,146 and 3,315,831 at March 31, 2016 and 2015, respectively, and are excluded from the calculation of diluted net loss per share for all periods presented because the effect is anti-dilutive. Included in the basic and diluted net loss per share calculation were RSUs awarded to directors that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number of shares underlying these vested RSUs at March 31, 2016 and 2015 was 59,197 and 23,665, respectively. The following table shows the computation of basic and diluted net loss per share of common stock for the three months ended March 31, 2016 and 2015: For the For the Three Months Ended Three Months Ended March 31, 2016 March 31, 2015 Numerator net loss $ (4,496 ) $ (3,093 ) Denominator weighted average number of shares outstanding, basic and diluted 10,407,430 9,337,275 Net loss per share, basic and diluted $ (0.43 ) $ (0.33 ) Recently Issued Accounting Pronouncements In May 2014, the FASB issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers. In February 2016, the FASB issued ASU 2016-02, Leases In January 2016, the FASB issued ASU 2016-01, Financial Instruments: Recognition and Measurement of Financial Assets and Financial Liabilities In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting |
Restricted Short-Term Investmen
Restricted Short-Term Investments | 3 Months Ended |
Mar. 31, 2016 | |
Restricted Short-term Investments | |
Restricted Short-Term Investments | NOTE 3. RESTRICTED SHORT-TERM INVESTMENTS The restricted short-term investments at March 31, 2016 and December 31, 2015 consist of certificates of deposit, which are classified as held-to-maturity. At March 31, 2016 and December 31, 2015, the restricted short-term investments were recorded at amortized cost, which approximates fair value. At March 31, 2016 and December 31, 2015, the certificates of deposit of $150 were classified as a current asset. These certificates of deposit are required as collateral under the Companys corporate credit card agreement and additional security for the Companys office space lease, and they automatically renew every twelve months. |
Inventories
Inventories | 3 Months Ended |
Mar. 31, 2016 | |
Inventory Disclosure [Abstract] | |
Inventories | NOTE 4. INVENTORIES Inventories are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, commercial pharmaceutical products, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of March 31, 2016 and December 31, 2015 was as follows: March 31, 2016 December 31, 2015 Raw materials $ 763 $ 775 Finished goods 470 637 Total inventories $ 1,233 $ 1,412 |
Prepaid Expenses and Other Curr
Prepaid Expenses and Other Current Assets | 3 Months Ended |
Mar. 31, 2016 | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | |
Prepaid Expenses and Other Current Assets | NOTE 5. PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets consisted of the following: March 31, 2016 December 31, 2015 Prepaid insurance $ 143 $ 297 Other prepaid expenses 386 370 Deposits and other current assets 250 119 Total prepaid expenses and other current assets $ 779 $ 786 |
Intangible Assets and Goodwill
Intangible Assets and Goodwill | 3 Months Ended |
Mar. 31, 2016 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Intangible Assets and Goodwill | NOTE 6. INTANGIBLE ASSETS AND GOODWILL The Companys intangible assets at March 31, 2016 consisted of the following: Amortization periods Accumulated Net (in years) Cost amortization Carrying value Patents 17-19 years $ 104 $ (1 ) $ 103 Trademarks Indefinite 137 - 137 Customer relationships 3-15 years 2,998 (363 ) 2,635 Trade name 5 years 16 (5 ) 11 Non-competition clause 3-4 years 294 (122 ) 172 State pharmacy licenses 25 years 45 (4 ) 41 $ 3,594 $ (494 ) $ 3,100 Amortization expense for intangible assets for the three months ended March 31, 2016 was as follows: For the For the Three Months Ended Three Months Ended March 31, 2016 March 31, 2015 Customer relationships $ 66 $ 63 Trade name 1 1 Non-competition clause 23 18 State pharmacy licenses 1 - $ 91 $ 82 Estimated future amortization expense for the Companys intangible assets at March 31, 2016 is as follows: Remainder of 2016 $ 276 2017 367 2018 221 2019 210 2020 208 Thereafter 1,818 $ 3,100 There have been no changes in the carrying value of the Companys goodwill during the three months ended March 31, 2016. |
Accounts Payable and Accrued Ex
Accounts Payable and Accrued Expenses | 3 Months Ended |
Mar. 31, 2016 | |
Payables and Accruals [Abstract] | |
Accounts Payable and Accrued Expenses | NOTE 7. ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses consisted of the following: March 31, 2016 December 31, 2015 Accounts payable $ 4,044 $ 3,185 Deferred rent 63 63 Accrued interest (see Note 8) 111 90 Accrued exit fee for note payable (see Note 8) 500 500 Building lease liability(1) 35 46 Other accrued expenses (2) - 23 Total accounts payable and accrued expenses 4,753 3,907 Less: Current portion (4,253 ) (3,407 ) Non-current total accrued expenses $ 500 $ 500 (1) In September 2014, the Company relocated its primary operations to a 7,565 square foot office facility in San Diego, California. In February 2015, the Company entered into a sublease agreement to sublet 3,874 square feet of its previously occupied offices through the remaining term of the lease at a monthly rent amount of $8. The Company recognized a loss of approximately $117 during the year ended December 31, 2014 related to the estimated remaining lease liability, net of expected sublease income, of the previously occupied offices. The obligations were discounted based on current prevailing market rates. (2) The amount consists of a $23 stock-based compensation accrual at December 31, 2015 related to stock options to be granted for consulting services provided. The stock options were granted during the three months ended March 31, 2016 and the $23 was recorded to additional paid-in-capital. |
Debt
Debt | 3 Months Ended |
Mar. 31, 2016 | |
Debt Disclosure [Abstract] | |
Debt | NOTE 8. DEBT Senior Note - 2015 On May 11, 2015, the Company entered into a loan and security agreement (the Loan Agreement) with IMMY Funding LLC, an affiliate of Life Sciences Alternative Funding LLC (the Lender), as lender and collateral agent. Pursuant to the terms of the Loan Agreement, as amended in January 2016, the Lender made available to the Company a term loan in the aggregate principal amount of up to $10,000, all of which was drawn on May 11, 2015. The term loans bear interest at a fixed per-annum rate of 12.5% and allows for 2% of the interest to be paid-in-kind until either February 2017 or May 2017, such date dependent upon the Companys ability to meet certain revenue or cash balance measures. The Company is permitted to pay interest only for the first three years and after the end of the interest-only period, we will be required to pay interest, plus repayments of the principal amount of the term loans, in 36 equal monthly installments. The interest-only period may be reduced to 20 months if the Company does not meet certain minimum revenue or cash balance requirements and the Company would be required to pay interest, plus repayments of the principal amount of the term loan, in 24 equal monthly installments. All amounts owed under the Loan Agreement, including a final fee of 5% of the aggregate principal amount of the term loan, will be due on the earlier of May 11, 2021, or 24 months after the end of the interest-only period. The Company incurred expenses of approximately $735 in connection with the Loan Agreement. The final fee and expenses are being amortized as interest expense over the term of the debt using the interest method and the related liability of $500 for the final fee is included in accrued expenses (see Note 7) in the accompanying condensed consolidated balance sheets. Pursuant to the terms of the Loan Agreement, the Company is bound by certain affirmative covenants setting forth actions that the Company must take during the term of the Loan Agreement, including, among others, certain information delivery requirements, obligations to maintain certain insurance and certain notice requirements. Additionally, the Company is bound by certain negative covenants setting forth actions that the Company may not take during the term of the Loan Agreement without the Lenders consent, including, among others, disposing of certain of the Companys or its subsidiaries business or property, incurring certain additional indebtedness, entering into certain merger, acquisition or change of control transactions, paying certain dividends or distributions on or repurchasing any of the Companys capital stock, or incurring any lien or other encumbrance on the Companys or its subsidiaries assets, subject to certain permitted exceptions. Upon the occurrence of an event of default under the Loan Agreement (subject to cure periods for certain events of default), all amounts owed by the Company thereunder may be declared immediately due and payable by the Lender. Events of default include, among others, the following: the occurrence of certain bankruptcy events; the failure to make payments under the Loan Agreement when due; the occurrence of a material adverse change in the business, operations or condition of the Company or any of its subsidiaries; the breach by the Company or its subsidiaries of certain of their material agreements with third parties; the initiation of certain regulatory enforcement actions against the Company or its subsidiaries; the rendering of certain types of fines or judgments against the Company or its subsidiaries; any breach by the Company or its subsidiaries of any covenant (subject to cure periods for certain covenants) made in the Loan Agreement; and the failure of any representation or warranty made by the Company or its subsidiaries in connection with the Loan Agreement to be correct in any material respect when made. The Companys obligations under the Loan Agreement are guaranteed on a secured basis by its wholly owned subsidiaries. Each of the Company and its subsidiaries has granted the Lender a security interest in substantially all of its personal property, rights and assets, including intellectual property rights and equity ownership, to secure the payment of all amounts owed under the Loan Agreement. In connection with the Loan Agreement, the Company has issued to the Lender a warrant to purchase up to 125,000 shares of the Companys common stock, which is exercisable immediately, had an exercise price of $7.85 per share upon issuance and has a term of 10 years. The relative fair value of the warrants was approximately $840 and was estimated using the Black-Scholes-Merton option pricing model with the following assumptions: fair value of the Companys common stock at issuance of $7.97 per share; ten-year contractual term; 109% volatility; 0% dividend rate; and a risk-free interest rate of 1.25%. The relative fair value of the warrants was recorded as a debt discount, decreasing notes payable and increasing additional paid-in capital on the accompanying condensed consolidated balance sheet. The debt discount is being amortized to interest expense over the term of the debt using the interest method. As described further, this warrant was amended in January 2016. For the three months ended March 31, 2016, debt discount amortization related to the Loan Agreement was $108. Convertible Senior Note 2016 On January 22, 2016, the Company entered into a note purchase agreement (the NPA) with, and issued an 8.00% Convertible Senior Secured Note in the principal amount of $3,000 (the Convertible Note) to, the Lender. Pursuant to the terms of the NPA, on the date thereof, the Company issued the Convertible Note to the Lender and, as consideration therefor, the Lender paid the Company in cash the full principal amount of the Convertible Note. The Company incurred expenses of approximately $228 in connection with the Convertible Note issuance and was recorded as a debt discount. The debt discount is being amortized as interest expense over the term of the debt using the interest method. Pursuant to the terms of the Convertible Note, the Company is obligated to pay interest on the principal amount of the Convertible Note monthly in cash at a fixed per-annum rate of 8.00%, and the Company is obligated to repay the full principal amount of the Convertible Note in cash on May 11, 2021. The Company is permitted to redeem the Convertible Note prior to its maturity at any time on or after March 1, 2018 for cash purchase prices equal to 109% - 105% of the outstanding principal amount of the Convertible Note, depending on the date of redemption. The Convertible Note was initially convertible by the holder at any time into shares of the Companys common stock at an effective conversion price of approximately $5.90 and subject to anti-dilution adjustment upon the Companys first equity financing while the Convertible Note is outstanding in which it receives gross proceeds of at least $3,000, if such equity financing is completed at a per share price that is less than the conversion rate of the Convertible Note, and also subject to adjustment upon stock combinations or splits, certain recapitalizations, stock or cash dividends or other distributions of property or equity rights. Additionally, in the event of certain change of control events affecting the Company, the Company may be required, at the option of the Lender, to repurchase the Convertible Note in cash for the greater of 105% of the outstanding principal amount of the Convertible Note or the value of the shares of common stock issuable upon conversion of the Convertible Note. The fair value of the embedded conversion feature was $2,322 and was recorded as a debt discount, decreasing notes payable and increasing derivative liability (see Note 10). The debt discount is being amortized to interest expense over the term of the debt using the interest method. For the three months ended March 31, 2016, debt discount amortization related to the Convertible Note was $154. In connection and concurrently with the execution of the NPA and the issuance of the Convertible Note, the Company and the Lender also entered into an amendment (the Loan Agreement Amendment) to the Loan Agreement (see above). The Loan Agreement Amendment modifies the terms of the Loan Agreement in order to eliminate the potential borrowing of a second term loan thereunder and to permit the Company to issue the Convertible Note. Additionally, the Company and the Lender entered into an amendment (the Warrant Amendment) to the warrants that were issued to the Lender in connection with the Loan Agreement. The Warrant Amendment modifies the terms of the warrants in order to reduce the exercise price thereof to $5.90 per share, which is consistent with the initial conversion rate of the Convertible Note, and to add an anti-dilution adjustment provision that is consistent with the same such provision in the Convertible Note. On March 16, 2016, upon the closing of a the Offering (see Note 9) and pursuant to the anti-dilution adjustment provisions of the Convertible Note and the Warrant Amendment, the effective conversion price of the Convertible Note was adjusted to approximately $3.60, and the exercise price of the warrants was adjusted to $3.60 per share (see also Note 10 for further accounting discussion of the warrant exercise price and conversion provisions and related derivative liabilities). Notes payable at March 31, 2016 was as follows: March 31, 2016 Senior Note - 2015 $ 10,000 Convertible Senior Note - 2016 3,000 Add: Interest paid-in-kind 181 Less: Discounts on notes (4,082 ) Less: Current portion - Long-term portion $ 9,099 Future minimum payments as of March 31, 2016 are as follows: Amount Remainder of 2016 $ 990 2017 1,435 2018 2,981 2019 4,423 2020 4,424 Thereafter 5,711 Total minimum payments 19,964 Less: amount representing interest and interest paid-in-kind (6,964 ) Notes payable, gross 13,000 Add: interest paid-in-kind 181 Less: unamortized discount (4,082 ) Notes payable and interest paid-in-kind, net of unamortized debt discount $ 9,099 |
Stockholders' Equity (Deficit)
Stockholders' Equity (Deficit) and Stock-Based Compensation | 3 Months Ended |
Mar. 31, 2016 | |
Equity [Abstract] | |
Stockholders' Equity (Deficit) and Stock-Based Compensation | NOTE 9. STOCKHOLDERS EQUITY (DEFICIT) AND STOCK-BASED COMPENSATION Common Stock In March 2016, the Company entered into an underwriting agreement (the Underwriting Agreement) with National Securities Corporation (the Representative), as the representative of the several underwriters named therein (collectively, the Underwriters), pursuant to which the Company agreed to sell to the Underwriters, and the Underwriters agreed, severally and not jointly, to purchase from the Company, in a firm-commitment public offering (the Offering), 2,900,000 shares of the Companys common stock and up to an additional 435,000 shares of the Companys common stock within 45 days from the date of the Underwriting Agreement to cover over-allotments, if any. Pursuant to the terms of the Underwriting Agreement, the Underwriters sold the shares of Common Stock to the public at a public offering price of $3.60 per share. The Offering, including the Underwriters exercise of the over-allotment option, closed on March 16, 2016. Upon the closing of the Offering, the Company sold 3,335,000 shares of common stock and received net proceeds of $11,088, after deducting the underwriting discount and the offering expenses payable by the Company. In November 2015, the Company entered into a Controlled Equity Offering SM During the three months ended March 31, 2016, 11,893 shares of the Companys common stock underlying RSUs issued to directors vested, but the issuance and delivery of these shares are deferred until the director resigns. During the three months ended March 31, 2016, the Company issued a total of 15,000 shares of common stock as a result of option exercises. The Company received $55 in cash proceeds for the issuance of the shares of common stock upon the exercise pursuant to exercise provisions of stock options to purchase 15,000 shares of common stock with exercise price of $3.68 per share. Preferred Stock At March 31, 2016, the Company had 5,000,000 shares of preferred stock, $0.001 par value, authorized and no shares of preferred stock issued and outstanding. Stock Option Plan On September 17, 2007, the Companys Board of Directors and stockholders adopted the Companys 2007 Incentive Stock and Awards Plan, which was subsequently amended on November 5, 2008, February 26, 2012, July 18, 2012, May 2, 2013 and September 27, 2013 (as amended, the Plan). As of March 31, 2016, the Plan provides for the issuance of a maximum of 5,000,000 shares of the Companys common stock. The purpose of the Plan is to provide an incentive to attract and retain directors, officers, consultants, advisors and employees whose services are considered valuable, to encourage a sense of proprietorship and to stimulate an active interest of such persons in the Companys development and financial success. Under the Plan, the Company is authorized to issue incentive stock options intended to qualify under Section 422 of the Internal Revenue Code, non-qualified stock options, restricted stock units and restricted stock. The Plan is administered by the Compensation Committee of the Companys Board of Directors. Stock Options A summary of stock option activity under the Plan for the three months ended March 31, 2016 is as follows: Number of shares Weighted Avg. Exercise Price Weighted Avg. Remaining Contractual Life Aggregate Intrinsic Value Options outstanding - January 1, 2016 1,544,026 $ 7.03 Options granted 18,850 $ 5.54 Options exercised (15,000 ) $ 3.68 Options cancelled/forfeit (4,313 ) $ 6.46 Options outstanding - March 31, 2016 1,543,563 $ 7.04 5.65 $ 196,275 Options exercisable 700,669 $ 6.36 5.79 $ 196,250 Options vested and expected to vest 1,459,274 $ 7.01 5.67 $ 196,273 The aggregate intrinsic value in the table above represents the total pre-tax amount of the proceeds, net of exercise price, which would have been received by option holders if all option holders had exercised and immediately sold all options with an exercise price lower than the market price on March 31, 2016, based on the closing price of the Companys common stock of $3.97 on that date. The aggregate intrinsic value of stock options exercised during the three months ended March 31, 2016 was approximately $29. During the three months ended March 31, 2016, the Company granted stock options to certain employees and consultants. The stock options were granted with an exercise price equal to the current market price of the Companys common stock, as reported by the securities exchange on which the common stock was then listed, at the grant date and have contractual terms of 10 years. Vesting terms for options granted to employees and consultants during the three months ended March 31, 2016 typically included one of the following vesting schedules: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over three years; or 100% vesting associated with the provision or completion of services provided under contracts with consultants. Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plan) and in the event of certain modifications to the option award agreement. The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model. The expected volatility is based on the historical volatilities of the common stock of the Company and comparable publicly traded companies based on the Companys belief that it currently has limited relevant historical data regarding the volatility of its stock price on which to base a meaningful estimate of expected volatility. The expected term of options granted was determined in accordance with the simplified approach, as the Company has limited, relevant, historical data on employee exercises and post-vesting employment termination behavior. The expected risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates. For option grants to employees and directors, the Company assigns a forfeiture factor of 10%. These factors could change in the future, which would affect the determination of stock-based compensation expense in future periods. Utilizing these assumptions, the fair value is determined at the date of grant. The table below illustrates the fair value per share determined by the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees: 2016 Weighted-average fair value of options granted $ 4.41 Expected terms (in years) 6.11 Expected volatility 101 - 102 % Risk-free interest rate 1.52 - 1.70 % Dividend yield - The table below illustrates the fair value per share determined by the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to consultants: 2016 Weighted-average fair value of options granted $ 4.37 Expected terms (in years) 10.00 Expected volatility 104 % Risk-free interest rate 1.14 % Dividend yield - The following table summarizes information about stock options outstanding and exercisable at March 31, 2016: Options Outstanding Options Exercisable Weighted Average Weighted Weighted Remaining Average Average Number Contractual Exercise Number Exercise Range of Exercise Prices Outstanding Life in Years Price Exercisable Price $2.40 125,000 5.82 $ 2.40 125,000 $ 2.40 $3.96 - $4.50 194,623 4.19 $ 4.31 156,503 $ 4.36 $5.49 - $7.99 970,353 5.83 $ 7.53 199,302 $ 6.72 $8.06 - $8.99 248,557 6.07 $ 8.90 214,834 $ 8.93 $42.80 5,030 4.37 $ 42.80 5,030 $ 42.80 1,543,563 5.65 $ 7.04 700,669 $ 6.36 As of March 31, 2016, there was approximately $3,998 of total unrecognized compensation expense related to unvested stock options granted under the Plan. That expense is expected to be recognized over the weighted-average remaining vesting period of 3.7 years. The stock-based compensation for all stock options was $658 during the three months ended March 31, 2016. Restricted Stock Units Restricted stock unit, or RSU, awards are granted subject to certain vesting requirements and other restrictions, including performance and market-based vesting criteria. The grant date fair value of the RSUs, which has been determined based upon the market value of the Companys common stock on the grant date, is expensed over the vesting period of the RSUs. Unvested portions of RSUs issued to consultants are remeasured on an interim basis until vesting criteria is met. A summary of the Companys RSU activity and related information for the three months ended March 31, 2016 is as follows: Number of RSUs Weighted Average Grant Date Fair Value RSUs unvested - January 1, 2016 1,487,961 $ 3.18 RSUs vested (11,893 ) $ 7.93 RSUs unvested at March 31, 2016 1,476,068 $ 3.19 As of March 31, 2016, the total unrecognized compensation expense related to unvested RSUs was approximately $1,153, which is expected to be recognized over a weighted-average period of 0.4 years, based on the vesting schedules of the applicable RSUs. The stock-based compensation for RSUs during the three months ended March 31, 2016 was $406. Warrants From time to time, the Company issues warrants to purchase shares of the Companys common stock to investors, lenders (see Note 8), underwriters and other non-employees for services rendered or to be rendered in the future. A summary of warrant activity for the three months ended March 31, 2016 is as follows: Number of Shares Subject to Warrants Outstanding Weighted Avg. Exercise Price Warrants outstanding - January 1, 2016 240,688 $ 7.41 Granted - Exercised - Expired/forfeited - Warrants outstanding and exercisable - March 31, 2016 240,688 $ 5.20 Weighted average remaining contractual life of the outstanding warrants in years - March 31, 2016 5.74 The fair value of each warrant is estimated on the date of grant using the Black-Scholes-Merton option pricing model. A list of the warrants outstanding as of March 31, 2016 is included in the following table: Warrants Outstanding Warrants Exercisable Warrants Exercise Warrants Expiration Warrant Series Issue Date Outstanding Price Exercisable Date Lender warrants (see Note 8) 5/11/2015 125,000 $ 3.60 125,000 5/11/2025 Underwriter Warrants 2/7/2013 55,688 $ 5.25 55,688 2/7/2018 Warrants issued to investor relations consultant 7/19/2013 60,000 $ 8.50 60,000 7/19/2018 240,688 $ 5.20 240,688 The Company recorded stock-based compensation related to equity instruments granted to employees, directors and consultants as follows: For the For the Three Months Ended Three Months Ended March 31, 2016 March 31, 2015 Employees - selling and marketing $ 120 $ 68 Employees - general and administrative 885 521 Directors - general and administrative 59 45 Consultants - selling and marketing - 24 Total $ 1,064 $ 658 |
Derivative Instruments
Derivative Instruments | 3 Months Ended |
Mar. 31, 2016 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Derivative Instruments | NOTE 10. DERIVATIVE INSTRUMENTS During the three months ended March 31, 2016, the Company modified certain common stock purchase warrants issued in conjunction with debt which are detachable, or free standing, instruments. The warrants were considered a derivative liability upon modification and the estimated fair value of the warrants was reclassified from equity to liabilities. In addition, the Company recorded a derivative liability and debt discount associated with the estimated fair value of the embedded conversion feature in the Convertible Note (see Note 8). Both instruments contained a provision which allowed for one-time adjustments to their exercise or conversion prices. The one-time adjustment occurred upon the closing of the Companys underwritten public offering of its common stock (see Note 9), on March 16, 2016, whereby the conversion and exercise prices were adjusted from $5.90 to $3.60 per share. At the time of the one-time adjustment, the Company reclassified the derivative liabilities to equity based on their estimated fair value at that time. The Company estimated the fair value of the derivative liabilities utilizing Level 3 inputs. The Company used the Black-Scholes-Merton option pricing model as it embodies all of the requisite assumptions (including trading volatility, remaining term to maturity, market price, strike price, and risk-free rates) necessary to value these instruments. The table below illustrates the fair value per share determined by the Black-Scholes-Merton option pricing model with the following assumptions used for valuing derivative liabilities: 2016 Expected volatility 103 - 111 % Risk-free interest rate 1.22 - 1.70 % Dividend yield - The Company estimated expected terms based on the remaining contractual life of the instruments on the date of the fair value measurement. The warrant expires on May 11, 2025 and the convertible note matures on May 11, 2022. The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs: March 31, 2016 Warrant derivative liability: Balance at January 1, 2016 $ - Modification of warrant and reclassification from equity to liabilities 675 Change in fair value (211 ) Reclassification from liabilities to equity upon closing of public equity offering (464 ) Balance at March 31, 2016 $ - Embedded conversion feature derivative liability: Balance at January 1, 2016 $ - Embedded conversion feature in Convertible Note issued 2,322 Change in fair value 324 Reclassification from liabilities to equity upon closing of public equity offering (2,646 ) Balance at March 31, 2016 $ - |
Commitments and Contingencies
Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2016 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | NOTE 11. COMMITMENTS AND CONTINGENCIES Contingent Acquisition Obligation On April 1, 2014, the Company acquired all of the outstanding membership interests of Pharmacy Creations, LLC (PC). The sellers of PC, are entitled to receive certain payments including contingent consideration upon certain conditions if PC earns revenue of between $3,500 and $7,500 during the 12 month period ended March 31, 2016, an aggregate of that number of shares of Imprimis common stock equal to the amount that such revenue exceeds $3,500,000 divided by 18.5882, rounded down to the lower whole number (not to exceed 215,190 shares). The estimated fair value of the contingent acquisition obligation is $483 and is included in the contingent acquisition obligation in the accompanying condensed balance sheets at March 31, 2016 and December 31, 2015. Legal Urigen, et. al, Litigation On October 2014, the Company entered into a license agreement (the Urigen License) with Urigen Pharmaceuticals, Inc. (Urigen), pursuant to which Urigen granted to the Company a license under certain U.S. patents and patent applications to develop and sell in the U.S. Urigens URG101 product, a heparin and alkalinized lidocaine compounded formulation for the prevention or treatment of disorders of the lower urinary tract. The Company, as the plaintiff, filed civil action in the San Diego Superior Court against Urigen in December 2015, wherein the Company outlined serious concerns regarding material failures and inaccuracies of the representation and warranties provided by Urigen in the Urigen License, which have affected the Companys ability to realize the expected benefit of the Urigen License. Urigen filed a cross-complaint in April 2016 for breach of contract asserting unpaid royalties totaling $698 and requesting a decree to cancel the Urigen Agreement. The Company filed another complaint in May 2016 with the U.S. District Court for the Southern District of California for declaratory judgment of the invalidity of the core patent filing related to Urigens URG 101. General and Other In the ordinary course of business, the Company may face various claims brought by third parties and the Company may, from time to time, make claims or take legal actions to assert the Companys rights, including intellectual property disputes, contractual disputes and other commercial disputes. Any of these claims could subject the Company to litigation. Management believes the outcomes of currently pending claims are not likely to have a material effect on the Companys consolidated financial position and results of operations. Indemnities In addition to the indemnification provisions contained in the Companys charter documents, the Company generally enters into separate indemnification agreements with each of the Companys directors and officers. These agreements require the Company, among other things, to indemnify the director or officer against specified expenses and liabilities, such as attorneys fees, judgments, fines and settlements, paid by the individual in connection with any action, suit or proceeding arising out of the individuals status or service as the Companys director or officer, other than liabilities arising from willful misconduct or conduct that is knowingly fraudulent or deliberately dishonest, and to advance expenses incurred by the individual in connection with any proceeding against the individual with respect to which the individual may be entitled to indemnification by the Company. The Company also indemnifies its lessors in connection with its facility leases for certain claims arising from the use of the facilities. These indemnities do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not incurred any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities in the accompanying condensed consolidated balance sheets. Asset Purchase, License and Commission Agreements The Company has acquired intellectual property rights related to certain proprietary innovations from certain inventors (the Inventors) through multiple asset purchase, license and commission agreements. In consideration for the acquisition of the intellectual property rights, the Company is obligated to make certain milestone payments related to patent and regulatory filings to the Inventors and also make payments, in one instance a minimum annual amount, based on certain percentages of revenues and net sales amounts, as defined within the respective agreements. During the three months ended March 31, 2016 and 2015, the Company recognized $361 and $2 in expense amounts related to these agreements. Such amounts are included in cost of sales and sales and marketing expenses in the accompanying condensed consolidated statements of operations. |
Segment Information and Concent
Segment Information and Concentrations | 3 Months Ended |
Mar. 31, 2016 | |
Segment Reporting [Abstract] | |
Segment Information and Concentrations | NOTE 12. SEGMENT INFORMATION AND CONCENTRATIONS The Company operates its business on the basis of a single reportable segment, which is the business of developing proprietary drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services. The Companys chief operating decision-maker is the Chief Executive Officer, who evaluates the Company as a single operating segment. The Company categorizes revenues by geographic area based on selling location. All operations are currently located in the U.S.; therefore, total revenues for 2016 and 2015 are attributed to the U.S. All long-lived assets at March 31, 2016 and December 31, 2015 are located in the U.S. The Company sells its compounded formulations to a large number of customers. Less than 10% of the Companys total pharmacy sales were derived from a single customer for the three months ended March 31, 2016 and 2015. The Company receives its active pharmaceutical ingredients from three main suppliers. These suppliers collectively accounted for 63% and 67% respectively, of active pharmaceutical ingredient purchases during the three months ended March 31, 2016 and 2015. |
Subsequent Events
Subsequent Events | 3 Months Ended |
Mar. 31, 2016 | |
Subsequent Events [Abstract] | |
Subsequent Events | NOTE 13. SUBSEQUENT EVENTS The Company has performed an evaluation of events occurring subsequent to March 31, 2016 through the filing date of this Quarterly Report. Based on its evaluation, nothing other than the events described below needs to be disclosed. In May 2016, the Company issued 200,000 shares of its common stock to Mark L. Baum, its CEO, related to the vesting of 200,000 RSUs. |
Summary of Significant Accoun19
Summary of Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2016 | |
Accounting Policies [Abstract] | |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management are, among others, allowance for doubtful accounts and contractual adjustments, realizability of inventories, valuation of deferred taxes, goodwill and intangible assets, recoverability of long-lived assets and goodwill, valuation of contingent acquisition obligations and deferred acquisition obligations, valuation of notes payable and derivative liabilities, and valuation of stock-based compensation issued to employees and non-employees. Actual results could differ from those estimates. |
Liquidity | Liquidity The Company has incurred significant operating losses and negative cash flows from operations since its inception. The Company incurred net losses of $4,496 and $3,093 for the three months ended March 31, 2016 and 2015, respectively, and had an accumulated deficit of $62,260 and $57,764 as of March 31, 2016 and December 31, 2015, respectively. In addition, the Company used cash in operating activities of $2,301 and $2,275 for the three months ended March 31, 2016 and 2015, respectively. While there is no assurance, the Company believes its existing cash resources and restricted investments of approximately $11,971 at March 31, 2016, will be sufficient to sustain the Companys planned level of operations for at least the next twelve months. However, estimates of operating expenses and working capital requirements could be incorrect, and the Company could use its cash resources faster than anticipated. Further, some or all of the ongoing or planned activities may not be successful and could result in further losses. The Company may seek to increase liquidity and capital resources by one or more measures, to the extent necessary. These measures may include, but are not limited to, the following: obtaining financing through the issuance of equity, debt, or convertible securities; and working to increase revenue growth through pharmacy sales. There is no guarantee that the Company will be able to obtain capital when needed on terms it deems as acceptable, or at all. |
Concentrations of Credit Risk | Concentrations of Credit Risk The Company places its cash with financial institutions deemed by management to be of high credit quality. The Federal Deposit Insurance Corporation (FDIC) provides basic deposit coverage with limits up to $250 per owner. At March 31, 2016, the Company had approximately $11,300 in cash deposits in excess of FDIC limits. |
Accounts Receivable | Accounts Receivable Accounts receivable are stated net of allowances for doubtful accounts and contractual adjustments. The accounts receivable balance primarily includes amounts due from customers the Company has invoiced or from third-party providers (e.g., insurance companies and governmental agencies), but for which payment has not been received. Charges to bad debt are based on both historical write-offs and specifically identified receivables. Contractual adjustments are determined by the amount expected to be collected from third-party providers. Accounts receivable are presented net of allowances for doubtful accounts and contractual adjustments in the amount of $180 as of March 31, 2016 and December 31, 2015. |
Revenue Recognition and Deferred Revenue | Revenue Recognition and Deferred Revenue The Company recognizes revenues when all of the following criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. The Companys revenues consist of sales of certain of the Companys proprietary compounded drug formulations and non-proprietary formulations and products. Product Revenues Determination of criteria (3) and (4) is based on managements judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Estimated returns and allowances and other adjustments are provided for in the same period during which the related sales are recorded. The Company will defer any revenues received for a product that has not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered and no refund will be required. License Revenues License arrangements may consist of non-refundable upfront license fees, data transfer fees, research reimbursement payments, exclusive license rights to patented or patent pending compounds, technology access fees, and various performance or sales milestones. These arrangements can be multiple element arrangements. Non-refundable fees that are not contingent on any future performance by the Company and require no consequential continuing involvement on the part of the Company are recognized as revenue when the license term commences and the licensed data, technology, compounded drug preparation and/or other deliverable is delivered. Such deliverables may include physical quantities of compounded drug preparations, design of the compounded drug preparations and structure-activity relationships, the conceptual framework and mechanism of action, and rights to the patents or patent applications for such compounded drug preparations. The Company defers recognition of non-refundable fees if it has continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee and that are separate and independent of the Companys performance under the other elements of the arrangement. In addition, if the Companys continued involvement is required, through research and development services that are related to its proprietary know-how and expertise of the delivered technology or can only be performed by the Company, then such non-refundable fees are deferred and recognized over the period of continuing involvement. Guaranteed minimum annual royalties are recognized on a straight-line basis over the applicable term. |
Debt Issuance Costs and Debt Discount | Debt Issuance Costs and Debt Discount Debt issuance costs and the debt discount are recorded net of notes payable in the condensed consolidated balance sheets. Amortization expense of debt issuance costs and the debt discount is calculated using the effective interest method over the term of the debt and is recorded in interest expense in the accompanying condensed consolidated statements of operations. |
Fair Value Measurements | Fair Value Measurements Fair value measurements are determined based on the assumptions that market participants would use in pricing an asset or liability. GAAP establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The established fair value hierarchy prioritizes the use of inputs used in valuation methodologies into the following three levels: ● Level 1: Applies to assets or liabilities for which there are quoted prices (unadjusted) for identical assets or liabilities in active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure fair value whenever available. ● Level 2: Applies to assets or liabilities for which there are significant other observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. ● Level 3: Applies to assets or liabilities for which there are significant unobservable inputs that reflect a reporting entitys own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, Level 3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method. At March 31, 2016 and December 31, 2015, the Company did not have any financial assets or liabilities that are measured on a recurring basis. At March 31, 2016 and December 31, 2015, the Companys financial instruments included cash and cash equivalents, restricted short-term investments, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, customer deposits, deferred acquisition obligations, notes payable and capital leases. The carrying amount of these financial instruments, except for deferred acquisition obligations and notes payable, approximates fair value due to the short-term maturities of these instruments. The Companys restricted short-term investments are carried at amortized cost, which approximates fair value. Based on borrowing rates currently available to the Company, the carrying values of the deferred acquisition obligations and notes payable, approximate their respective fair values. |
Derivative Instruments | Derivative Instruments The Company accounts for free-standing derivative instruments and hybrid instruments that contain embedded derivative features as either assets or liabilities in the condensed consolidated balance sheets and are measured at fair value with gains or losses recognized in earnings. Embedded derivatives that are not clearly and closely related to the host contract are bifurcated and are recognized at fair value with changes in fair value recognized as either a gain or loss in earnings. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models, giving consideration to all of the rights and obligations of each instrument. The Company estimates the fair value of derivative instruments and hybrid instruments using various techniques (and combinations thereof) that are considered to be consistent with the objective of measuring fair value. In selecting the appropriate technique, the Company considers, among other factors, the nature of the instrument, the market risks that it embodies and the expected means of settlement. The Company generally uses the Black-Scholes-Merton option pricing model, adjusted for the effect of dilution, because it embodies all of the requisite assumptions (including trading volatility, estimated terms, dilution and risk-free rates) necessary to fair value these instruments. Estimating the fair value of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. Increases in the trading price of the Companys common stock and increases in fair value during a given financial quarter result in the application of non-cash derivative expense. Conversely, decreases in the trading price of the Companys common stock and decreases in fair value during a given financial quarter would result in the application of non-cash derivative income. |
Third Party Billing and Collection Agreements | Third Party Billing and Collection Agreements In connection with its acquisition of South Coast Specialty Compounding, Inc. D/B/A Park Compounding (Park), the Company entered into a billing and collection agreement with a third party to assist in the billing and collection of workers compensation claims. Under the terms of the agreement, the Company is obligated to pay a fixed fee to the third party equal to 55% of the amounts billed and collected under the workers compensation claims. The Company accrues for such fees in accounts payable and accrued expenses in the accompanying condensed consolidated balance sheets. Total billing and collection management expense under this agreement for the three months ended March 31, 2016 and 2015 were $15 and $6, respectively, and is included in selling and marketing expenses in the accompanying condensed consolidated statements of operations. The amounts due under the agreement as of March 31, 2016 and December 31, 2015 was $59 and $81, respectively. |
Stock-Based Compensation | Stock-Based Compensation All stock-based payments to employees, directors and consultants, including grants of stock options, warrants, restricted stock units (RSUs) and restricted stock, are recognized in the condensed consolidated financial statements based upon their estimated fair values. The Company uses the Black-Scholes-Merton option pricing model and Monte Carlo Simulation to estimate the fair value of stock-based awards. The estimated fair value is determined at the date of grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates. The Companys accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows Financial Accounting Standards Board (FASB) guidance. As such, the value of the applicable stock-based compensation is periodically remeasured and income or expense is recognized during the vesting terms of the equity instruments. The measurement date for the estimated fair value of the equity instruments issued is the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendors performance is complete. In the case of equity instruments issued to consultants, the estimated fair value of the equity instrument is primarily recognized over the term of the consulting agreement. According to FASB guidance, an asset acquired in exchange for the issuance of fully vested, nonforfeitable equity instruments should not be presented or classified as an offset to equity on the grantors balance sheet once the equity instrument is granted for accounting purposes. Accordingly, the Company records the estimated fair value of nonforfeitable equity instruments issued for future consulting services as prepaid stock-based consulting expenses in its condensed consolidated balance sheets. |
Income Taxes | Income Taxes The Company accounts for income taxes under the provisions of FASB Accounting Standards Codification (ASC) 740, Income Taxes |
Basic and Diluted Net Loss per Common Share | Basic and Diluted Net Loss per Common Share Basic net loss per common share is computed by dividing net loss attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such as stock options and warrants, outstanding during the period. Basic and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. Common stock equivalents (using the treasury stock or if converted method) from deferred acquisition obligations, stock options, unvested RSUs and warrants were 4,134,146 and 3,315,831 at March 31, 2016 and 2015, respectively, and are excluded from the calculation of diluted net loss per share for all periods presented because the effect is anti-dilutive. Included in the basic and diluted net loss per share calculation were RSUs awarded to directors that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number of shares underlying these vested RSUs at March 31, 2016 and 2015 was 59,197 and 23,665, respectively. The following table shows the computation of basic and diluted net loss per share of common stock for the three months ended March 31, 2016 and 2015: For the For the Three Months Ended Three Months Ended March 31, 2016 March 31, 2015 Numerator net loss $ (4,496 ) $ (3,093 ) Denominator weighted average number of shares outstanding, basic and diluted 10,407,430 9,337,275 Net loss per share, basic and diluted $ (0.43 ) $ (0.33 ) |
Recently Issued Accounting Pronouncements | Recently Issued Accounting Pronouncements In May 2014, the FASB issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers. In February 2016, the FASB issued ASU 2016-02, Leases In January 2016, the FASB issued ASU 2016-01, Financial Instruments: Recognition and Measurement of Financial Assets and Financial Liabilities In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting |
Summary of Significant Accoun20
Summary of Significant Accounting Policies (Tables) | 3 Months Ended |
Mar. 31, 2016 | |
Accounting Policies [Abstract] | |
Schedule of Basic and Diluted Earnings Per Common Share | The following table shows the computation of basic and diluted net loss per share of common stock for the three months ended March 31, 2016 and 2015: For the For the Three Months Ended Three Months Ended March 31, 2016 March 31, 2015 Numerator net loss $ (4,496 ) $ (3,093 ) Denominator weighted average number of shares outstanding, basic and diluted 10,407,430 9,337,275 Net loss per share, basic and diluted $ (0.43 ) $ (0.33 ) |
Inventories (Tables)
Inventories (Tables) | 3 Months Ended |
Mar. 31, 2016 | |
Inventory Disclosure [Abstract] | |
Schedule of Inventories | The composition of inventories as of March 31, 2016 and December 31, 2015 was as follows: March 31, 2016 December 31, 2015 Raw materials $ 763 $ 775 Finished goods 470 637 Total inventories $ 1,233 $ 1,412 |
Prepaid Expenses and Other Cu22
Prepaid Expenses and Other Current Assets (Tables) | 3 Months Ended |
Mar. 31, 2016 | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | |
Schedule of Prepaid Expenses and Other Current Assets | Prepaid expenses and other current assets consisted of the following: March 31, 2016 December 31, 2015 Prepaid insurance $ 143 $ 297 Other prepaid expenses 386 370 Deposits and other current assets 250 119 Total prepaid expenses and other current assets $ 779 $ 786 |
Intangible Assets and Goodwill
Intangible Assets and Goodwill (Tables) | 3 Months Ended |
Mar. 31, 2016 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Intangible Assets | The Companys intangible assets at March 31, 2016 consisted of the following: Amortization periods Accumulated Net (in years) Cost amortization Carrying value Patents 17-19 years $ 104 $ (1 ) $ 103 Trademarks Indefinite 137 - 137 Customer relationships 3-15 years 2,998 (363 ) 2,635 Trade name 5 years 16 (5 ) 11 Non-competition clause 3-4 years 294 (122 ) 172 State pharmacy licenses 25 years 45 (4 ) 41 $ 3,594 $ (494 ) $ 3,100 |
Schedule of Amortization Expenses for Intangible Assets | Amortization expense for intangible assets for the three months ended March 31, 2016 was as follows: For the For the Three Months Ended Three Months Ended March 31, 2016 March 31, 2015 Customer relationships $ 66 $ 63 Trade name 1 1 Non-competition clause 23 18 State pharmacy licenses 1 - $ 91 $ 82 |
Schedule of Estimated Future Amortization Expense | Estimated future amortization expense for the Companys intangible assets at March 31, 2016 is as follows: Remainder of 2016 $ 276 2017 367 2018 221 2019 210 2020 208 Thereafter 1,818 $ 3,100 |
Accounts Payable and Accrued 24
Accounts Payable and Accrued Expenses (Tables) | 3 Months Ended |
Mar. 31, 2016 | |
Payables and Accruals [Abstract] | |
Schedule of Accounts Payable and Accrued Expenses | Accounts payable and accrued expenses consisted of the following: March 31, 2016 December 31, 2015 Accounts payable $ 4,044 $ 3,185 Deferred rent 63 63 Accrued interest (see Note 8) 111 90 Accrued exit fee for note payable (see Note 8) 500 500 Building lease liability(1) 35 46 Other accrued expenses (2) - 23 Total accounts payable and accrued expenses 4,753 3,907 Less: Current portion (4,253 ) (3,407 ) Non-current total accrued expenses $ 500 $ 500 (1) In September 2014, the Company relocated its primary operations to a 7,565 square foot office facility in San Diego, California. In February 2015, the Company entered into a sublease agreement to sublet 3,874 square feet of its previously occupied offices through the remaining term of the lease at a monthly rent amount of $8. The Company recognized a loss of approximately $117 during the year ended December 31, 2014 related to the estimated remaining lease liability, net of expected sublease income, of the previously occupied offices. The obligations were discounted based on current prevailing market rates. (2) The amount consists of a $23 stock-based compensation accrual at December 31, 2015 related to stock options to be granted for consulting services provided. The stock options were granted during the three months ended March 31, 2016 and the $23 was recorded to additional paid-in-capital. |
Debt (Tables)
Debt (Tables) | 3 Months Ended |
Mar. 31, 2016 | |
Debt Disclosure [Abstract] | |
Summary of Notes Payable | Notes payable at March 31, 2016 was as follows: March 31, 2016 Senior Note - 2015 $ 10,000 Convertible Senior Note - 2016 3,000 Add: Interest paid-in-kind 181 Less: Discounts on notes (4,082 ) Less: Current portion - Long-term portion $ 9,099 |
Summary of Future Minimum Payments | Future minimum payments as of March 31, 2016 are as follows: Amount Remainder of 2016 $ 990 2017 1,435 2018 2,981 2019 4,423 2020 4,424 Thereafter 5,711 Total minimum payments 19,964 Less: amount representing interest and interest paid-in-kind (6,964 ) Notes payable, gross 13,000 Add: interest paid-in-kind 181 Less: unamortized discount (4,082 ) Notes payable and interest paid-in-kind, net of unamortized debt discount $ 9,099 |
Stockholders' Equity (Deficit26
Stockholders' Equity (Deficit) and Stock-Based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2016 | |
Equity [Abstract] | |
Schedule of Stock Option Plan Activity | A summary of stock option activity under the Plan for the three months ended March 31, 2016 is as follows: Number of shares Weighted Avg. Exercise Price Weighted Avg. Remaining Contractual Life Aggregate Intrinsic Value Options outstanding - January 1, 2016 1,544,026 $ 7.03 Options granted 18,850 $ 5.54 Options exercised (15,000 ) $ 3.68 Options cancelled/forfeit (4,313 ) $ 6.46 Options outstanding - March 31, 2016 1,543,563 $ 7.04 5.65 $ 196,275 Options exercisable 700,669 $ 6.36 5.79 $ 196,250 Options vested and expected to vest 1,459,274 $ 7.01 5.67 $ 196,273 |
Schedule of Fair Value Assumption | The table below illustrates the fair value per share determined by the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees: 2016 Weighted-average fair value of options granted $ 4.41 Expected terms (in years) 6.11 Expected volatility 101 - 102 % Risk-free interest rate 1.52 - 1.70 % Dividend yield - The table below illustrates the fair value per share determined by the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to consultants: 2016 Weighted-average fair value of options granted $ 4.37 Expected terms (in years) 10.00 Expected volatility 104 % Risk-free interest rate 1.14 % Dividend yield - |
Schedule of Shares Outstanding and Exercisable | The following table summarizes information about stock options outstanding and exercisable at March 31, 2016: Options Outstanding Options Exercisable Weighted Average Weighted Weighted Remaining Average Average Number Contractual Exercise Number Exercise Range of Exercise Prices Outstanding Life in Years Price Exercisable Price $2.40 125,000 5.82 $ 2.40 125,000 $ 2.40 $3.96 - $4.50 194,623 4.19 $ 4.31 156,503 $ 4.36 $5.49 - $7.99 970,353 5.83 $ 7.53 199,302 $ 6.72 $8.06 - $8.99 248,557 6.07 $ 8.90 214,834 $ 8.93 $42.80 5,030 4.37 $ 42.80 5,030 $ 42.80 1,543,563 5.65 $ 7.04 700,669 $ 6.36 |
Schedule of Restricted Stock Units Activity | A summary of the Companys RSU activity and related information for the three months ended March 31, 2016 is as follows: Number of RSUs Weighted Average Grant Date Fair Value RSUs unvested - January 1, 2016 1,487,961 $ 3.18 RSUs vested (11,893 ) $ 7.93 RSUs unvested at March 31, 2016 1,476,068 $ 3.19 |
Schedule of Warrants Activity | A summary of warrant activity for the three months ended March 31, 2016 is as follows: Number of Shares Subject to Warrants Outstanding Weighted Avg. Exercise Price Warrants outstanding - January 1, 2016 240,688 $ 7.41 Granted - Exercised - Expired/forfeited - Warrants outstanding and exercisable - March 31, 2016 240,688 $ 5.20 Weighted average remaining contractual life of the outstanding warrants in years - March 31, 2016 5.74 |
Schedule of Warrants Outstanding and Warrants Exercisable | A list of the warrants outstanding as of March 31, 2016 is included in the following table: Warrants Outstanding Warrants Exercisable Warrants Exercise Warrants Expiration Warrant Series Issue Date Outstanding Price Exercisable Date Lender warrants (see Note 8) 5/11/2015 125,000 $ 3.60 125,000 5/11/2025 Underwriter Warrants 2/7/2013 55,688 $ 5.25 55,688 2/7/2018 Warrants issued to investor relations consultant 7/19/2013 60,000 $ 8.50 60,000 7/19/2018 240,688 $ 5.20 240,688 |
Schedule of Stock Based Compensation Granted to Employees Directors Consultants | The Company recorded stock-based compensation related to equity instruments granted to employees, directors and consultants as follows: For the For the Three Months Ended Three Months Ended March 31, 2016 March 31, 2015 Employees - selling and marketing $ 120 $ 68 Employees - general and administrative 885 521 Directors - general and administrative 59 45 Consultants - selling and marketing - 24 Total $ 1,064 $ 658 |
Derivative Instruments (Tables)
Derivative Instruments (Tables) | 3 Months Ended |
Mar. 31, 2016 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Schedule of Derivative Liabilities at Fair Value | The table below illustrates the fair value per share determined by the Black-Scholes-Merton option pricing model with the following assumptions used for valuing derivative liabilities: 2016 Expected volatility 103 - 111 % Risk-free interest rate 1.22 - 1.70 % Dividend yield - |
Fair Value at Reconciliation of Measured Liabilities | The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs: March 31, 2016 Warrant derivative liability: Balance at January 1, 2016 $ - Modification of warrant and reclassification from equity to liabilities 675 Change in fair value (211 ) Reclassification from liabilities to equity upon closing of public equity offering (464 ) Balance at March 31, 2016 $ - Embedded conversion feature derivative liability: Balance at January 1, 2016 $ - Embedded conversion feature in Convertible Note issued 2,322 Change in fair value 324 Reclassification from liabilities to equity upon closing of public equity offering (2,646 ) Balance at March 31, 2016 $ - |
Summary of Significant Accoun28
Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2016 | Mar. 31, 2015 | Dec. 31, 2015 | |
Net loss | $ 4,496 | $ 3,093 | |
Accumulated deficit | (62,260) | $ (57,764) | |
Net cash used in operating activity | (2,301) | $ (2,275) | |
Cash resources and restricted investments | 11,971 | ||
Deposit coverage limits by FDIC, per owner | 250 | ||
Cash deposits in excess of FDIC limits | 11,300 | ||
Accounts receivable, net of allowance for doubtful accounts | $ 180 | 180 | |
Restricted Stock Units (RSUs) [Member] | |||
Number of shares vested during the period | 59,197 | 23,665 | |
Deferred Acquisition Obligations, Stock Options, Unvested RSUs and Warrants [Member] | |||
Anti dulitive securities | 4,134,146 | 3,315,831 | |
Billing And Collection Agreement [Member] | Third Party [Member] | |||
Percentage of billing and collection amount | 55.00% | ||
Billing and collection management expense | $ 15 | $ 6 | |
Due to related party | $ 59 | $ 81 |
Summary of Significant Accoun29
Summary of Significant Accounting Policies - Schedule of Basic and Diluted Earnings Per Common Share (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | |
Mar. 31, 2016 | Mar. 31, 2015 | |
Accounting Policies [Abstract] | ||
Numerator - net loss | $ (4,496) | $ (3,093) |
Denominator - weighted average number of shares outstanding, basic and diluted | 10,407,430 | 9,337,275 |
Net loss per share, basic and diluted | $ (0.43) | $ (0.33) |
Restricted Short-Term Investm30
Restricted Short-Term Investments (Details Narrative) - USD ($) $ in Thousands | Mar. 31, 2016 | Dec. 31, 2015 |
Restricted Short-term Investments | ||
Certificate of deposit | $ 150 | $ 150 |
Inventories - Schedule of Inven
Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands | Mar. 31, 2016 | Dec. 31, 2015 |
Inventory Disclosure [Abstract] | ||
Raw materials | $ 763 | $ 775 |
Finished goods | 470 | 637 |
Total inventories | $ 1,233 | $ 1,412 |
Prepaid Expenses and Other Cu32
Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands | Mar. 31, 2016 | Dec. 31, 2015 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | ||
Prepaid insurance | $ 143 | $ 297 |
Other prepaid expenses | 386 | 370 |
Deposits and other current assets | 250 | 119 |
Total prepaid expenses and other current assets | $ 779 | $ 786 |
Intangible Assets and Goodwil33
Intangible Assets and Goodwill - Schedule of Intangible Assets (Details) $ in Thousands | 3 Months Ended |
Mar. 31, 2016USD ($) | |
Cost | $ 3,594 |
Accumulated amortization | (494) |
Net Carrying value | 3,100 |
Patents [Member] | |
Cost | 104 |
Accumulated amortization | (1) |
Net Carrying value | $ 103 |
Patents [Member] | Minimum [Member] | |
Amortization periods (in years) | 17 years |
Patents [Member] | Maximum [Member] | |
Amortization periods (in years) | 19 years |
Trademarks [Member] | |
Amortization periods description | Indefinite |
Cost | $ 137 |
Accumulated amortization | |
Net Carrying value | $ 137 |
Customer Relationships [Member] | |
Cost | 2,998 |
Accumulated amortization | (363) |
Net Carrying value | $ 2,635 |
Customer Relationships [Member] | Minimum [Member] | |
Amortization periods (in years) | 3 years |
Customer Relationships [Member] | Maximum [Member] | |
Amortization periods (in years) | 15 years |
Trade Name [Member] | |
Amortization periods (in years) | 5 years |
Cost | $ 16 |
Accumulated amortization | (5) |
Net Carrying value | 11 |
Non-Competition Clause [Member] | |
Cost | 294 |
Accumulated amortization | (122) |
Net Carrying value | $ 172 |
Non-Competition Clause [Member] | Minimum [Member] | |
Amortization periods (in years) | 3 years |
Non-Competition Clause [Member] | Maximum [Member] | |
Amortization periods (in years) | 4 years |
State Pharmacy Licenses [Member] | |
Amortization periods (in years) | 25 years |
Cost | $ 45 |
Accumulated amortization | (4) |
Net Carrying value | $ 41 |
Intangible Assets and Goodwil34
Intangible Assets and Goodwill - Schedule of Amortization Expenses for Intangible Assets (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2016 | Mar. 31, 2015 | |
Amortization of intangible assets | $ 91 | $ 82 |
Customer Relationships [Member] | ||
Amortization of intangible assets | 66 | 63 |
Trade Name [Member] | ||
Amortization of intangible assets | 1 | 1 |
Non-Competition Clause [Member] | ||
Amortization of intangible assets | 23 | $ 18 |
State Pharmacy Licenses [Member] | ||
Amortization of intangible assets | $ 1 |
Intangible Assets and Goodwil35
Intangible Assets and Goodwill - Schedule of Estimated Future Amortization Expense (Details) - USD ($) $ in Thousands | Mar. 31, 2016 | Dec. 31, 2015 |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
2,016 | $ 276 | |
2,017 | 367 | |
2,018 | 221 | |
2,019 | 210 | |
2,020 | 208 | |
Thereafter | 1,818 | |
Intangible assets | $ 3,100 | $ 3,135 |
Accounts Payable and Accrued 36
Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands | Mar. 31, 2016 | Dec. 31, 2015 | |
Payables and Accruals [Abstract] | |||
Accounts payable | $ 4,044 | $ 3,185 | |
Deferred rent | 63 | 63 | |
Accrued interest (see Note 8) | 111 | 90 | |
Accrued exit fee for note payable (see Note 8) | 500 | 500 | |
Building lease liability (1) | [1] | $ 35 | 46 |
Other accrued expenses (2) | [2] | 23 | |
Total accounts payable and accrued expenses | $ 4,753 | 3,907 | |
Less: Current portion | (4,253) | (3,407) | |
Non-current total accrued expenses | $ 500 | $ 500 | |
[1] | (1) In September 2014, the Company relocated its primary operations to a 7,565 square foot office facility in San Diego, California. In February 2015, the Company entered into a sublease agreement to sublet 3,874 square feet of its previously occupied offices through the remaining term of the lease at a monthly rent amount of $8. The Company recognized a loss of approximately $117 during the year ended December 31, 2014 related to the estimated remaining lease liability, net of expected sublease income, of the previously occupied offices. The obligations were discounted based on current prevailing market rates. | ||
[2] | (2) The amount consists of a $23 stock-based compensation accrual at December 31, 2015 related to stock options to be granted for consulting services provided. The stock options were granted during the three months ended March 31, 2016 and the $23 was recorded to additional paid-in-capital. |
Accounts Payable and Accrued 37
Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) (Parenthetical) $ in Thousands | 1 Months Ended | 3 Months Ended | 12 Months Ended | ||
Feb. 28, 2015USD ($)ft² | Mar. 31, 2016USD ($) | Dec. 31, 2014USD ($) | Dec. 31, 2015USD ($) | Sep. 30, 2014ft² | |
Payables and Accruals [Abstract] | |||||
Area of office space | ft² | 7,565 | ||||
Area of previous office space | ft² | 3,874 | ||||
Monthly rent amount | $ 8 | ||||
Recognized lease losses related to estimated remaining lease liability | $ 117 | ||||
Stock based compensation accrual | $ 23 | ||||
Additional paid-in-capital | $ 23 |
Debt (Details Narrative)
Debt (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands | Mar. 16, 2016 | Jan. 22, 2016 | May. 11, 2015 | Mar. 31, 2016 | Mar. 31, 2015 | Dec. 31, 2015 |
Loan due date | May 11, 2022 | |||||
Liability of final fee included in accrued expenses | $ 500 | $ 500 | ||||
Fair value of dividend rate | ||||||
Debt discount | $ 262 | |||||
Debt conversion price per share | $ 5.90 | |||||
Warrants exercise price per share | $ 3.60 | |||||
Loan Agreement [Member] | ||||||
Debt discount | 108 | |||||
Loan Agreement [Member] | Life Sciences Alternative Funding LLC [Member] | ||||||
Principal amount of loan | $ 10,000 | |||||
Loans bear interest | 12.50% | |||||
loans bear interest rate description | The term loans bear interest at a fixed per-annum rate of 12.5% and allows for 2% of the interest to be paid-in-kind until either February 2017 or May 2017, | |||||
Loan installments | 36 months | |||||
Percentage of loan agreement final fee | 5.00% | |||||
Loan due date | May 11, 2021 | |||||
Incurred expense debt | $ 735 | |||||
Liability of final fee included in accrued expenses | $ 500 | |||||
Issuance of warrants to purchase maximum number of shares | 125,000 | |||||
Common stock exercise price per share | $ 7.85 | |||||
Issuance of warrants to purchase of common stock expiration year | 10 years | |||||
Fair value of warrants | $ 840 | |||||
Fair value of common stock | $ 7.97 | |||||
Fair value of contractual term | 10 years | |||||
Common stock volatility rate | 109.00% | |||||
Fair value of dividend rate | 0.00% | |||||
Fair value of risk-free interest rate | 1.25% | |||||
Loan Agreement [Member] | Life Sciences Alternative Funding LLC [Member] | Minimum Revenue or Cash Balance [Member] | ||||||
Loan installments | 24 months | |||||
Note Purchase Agreement [Member] | Lender [Member] | 8.00% Convertible Senior Secured Note [Member] | ||||||
Loans bear interest | 8.00% | |||||
Loan due date | May 11, 2021 | |||||
Incurred expense debt | $ 228 | |||||
Debt discount | $ 154 | |||||
Convertible note principal amount | $ 3,000 | |||||
Convertible note fixed per annum rate | 8.00% | |||||
Convertible note description | The Company is permitted to redeem the Convertible Note prior to its maturity at any time on or after March 1, 2018 for cash purchase prices equal to 109% - 105% of the outstanding principal amount of the Convertible Note, depending on the date of redemption. | |||||
Debt conversion price per share | $ 5.90 | |||||
Proceeeds from convertible note | $ 3,000 | |||||
Percentage of repurchase convertible note in cash is greater than outstanding principal amount | 105.00% | |||||
Fair value of embedded conversion feature | $ 2,322 | |||||
Warrants exercise price per share | $ 3.60 |
Debt - Summary of Notes Payable
Debt - Summary of Notes Payable (Details) - USD ($) $ in Thousands | Mar. 31, 2016 | Dec. 31, 2015 |
Less: Discounts on notes | $ (8,495) | $ (8,336) |
Senior Note - 2015 [Member] | ||
Notes payable | 10,000 | |
Convertible Senior Note - 2016 [Member] | ||
Notes payable | 3,000 | |
Notes Payable [Member] | ||
Notes payable | 13,000 | |
Add: Interest paid-in-kind | 181 | |
Less: Discounts on notes | $ (4,082) | |
Less: Current portion | ||
Long-term portion | $ 9,099 |
Debt - Summary of Future Minimu
Debt - Summary of Future Minimum Payments (Details) - USD ($) $ in Thousands | Mar. 31, 2016 | Dec. 31, 2015 |
Less: unamortized discount | $ (8,495) | $ (8,336) |
Notes Payable [Member] | ||
Remainder of 2016 | 990 | |
2,017 | 1,435 | |
2,018 | 2,981 | |
2,019 | 4,423 | |
2,020 | 4,424 | |
Thereafter | 5,711 | |
Total minimum payments | 19,964 | |
Less: amount representing interest and interest paid-in-kind | (6,964) | |
Notes payable, gross | 13,000 | |
Add: interest paid-in-kind | 181 | |
Less: unamortized discount | (4,082) | |
Notes payable and interest paid-in-kind, net of unamortized debt discount | $ 9,099 |
Stockholders' Equity (Deficit41
Stockholders' Equity (Deficit) and Stock-Based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands | Mar. 16, 2016 | Mar. 31, 2016 | Nov. 30, 2015 | Mar. 31, 2016 | Mar. 31, 2015 |
Sale of stock price per share | $ 3.97 | $ 3.97 | |||
Proceeds from offering price | $ 11,088 | ||||
Shares issued upon exercise of stock options, shares | 15,000 | ||||
Shares issued upon exercise of stock options | $ 55 | ||||
Stock options to purchase shares of common stock | 15,000 | ||||
Stock option purchase of exercise price | $ 3.68 | ||||
Preferred stock, shares authorized | 5,000,000 | 5,000,000 | |||
Preferred stock, par value | $ 0.001 | $ 0.001 | |||
Preferred stock, shares issued | 0 | 0 | |||
Preferred stock, shares outstanding | 0 | 0 | |||
Intrinsic value of stock option exercised | $ 29 | ||||
Stock options granted with exercise price contractual terms | 10 years | ||||
Stock options granted vesting terms | During the three months ended March 31, 2016, the Company granted stock options to certain employees and consultants. The stock options were granted with an exercise price equal to the current market price of the Companys common stock, as reported by the securities exchange on which the common stock was then listed, at the grant date and have contractual terms of 10 years. Vesting terms for options granted to employees and consultants during the three months ended March 31, 2016 typically included one of the following vesting schedules: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over three years; or 100% vesting associated with the provision or completion of services provided under contracts with consultants. Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plan) and in the event of certain modifications to the option award agreement. | ||||
Percentage of forfeiture factor | 10.00% | ||||
Stock-based compensation | $ 1,064 | $ 658 | |||
Stock Options [Member] | |||||
Unrecognized compensation expense related to unvested stock options granted under the Plan | $ 3,998 | $ 3,998 | |||
Expense expected to recognize over the weighted-average remaining vesting period | 3 years 8 months 12 days | ||||
Stock-based compensation | $ 658 | ||||
2007 Incentive Stock and Awards Plan [Member] | |||||
Maximum number of common stock issuance under the plan | 5,000,000 | 5,000,000 | |||
Restricted Stock Units (RSUs) [Member] | |||||
Number of shares vested during the period | 59,197 | 23,665 | |||
Unrecognized compensation expense related to unvested stock options granted under the Plan | $ 1,153 | $ 1,153 | |||
Expense expected to recognize over the weighted-average remaining vesting period | 4 months 24 days | ||||
Stock-based compensation | $ 406 | ||||
Directors [Member] | Restricted Stock Units (RSUs) [Member] | |||||
Number of shares vested during the period | 11,893 | ||||
Sales Agreement [Member] | |||||
Percentage of cash commission | 3.00% | ||||
Proceeds from offering price | 2,625 | ||||
Available for future sales of shares | $ 2,096 | $ 2,096 | |||
Underwriting Agreement [Member] | Underwriters [Member] | |||||
Number of common stock shares issued for offering | 2,900,000 | ||||
Additional common stock shares issued during the period | 435,000 | ||||
Sale of stock price per share | $ 3.60 | ||||
Number of shares sold under the agreement | 3,335,000 | ||||
proceeds from sale of common stock approximately | $ 11,088 |
Stockholders' Equity (Deficit42
Stockholders' Equity (Deficit) and Stock-Based Compensation - Schedule of Stock Option Plan Activity (Details) $ / shares in Units, $ in Thousands | 3 Months Ended |
Mar. 31, 2016USD ($)$ / sharesshares | |
Number of shares, Options exercised | shares | 15,000 |
Weighted Avg. Exercise Price, Options granted | $ 3.68 |
Weighted Avg. Exercise Price, Exercisable Ending Balance | $ 7.04 |
Weighted Avg. Remaining Contractual Life, Options exercisable | 10 years |
Stock Option Plan [Member] | |
Number of shares, Outstanding, Beginning balance | shares | 1,544,026 |
Number of shares, Options granted | shares | 18,850 |
Number of shares, Options exercised | shares | (15,000) |
Number of shares, Options cancelled/forfeit | shares | (4,313) |
Number of shares, Outstanding, Ending balance | shares | 1,543,563 |
Number of shares, Options exercisable | shares | 700,669 |
Number of shares, Options vested and expected to vest | shares | 1,459,274 |
Weighted Avg. Exercise Price, Outstanding, Beginning balance | $ 7.03 |
Weighted Avg. Exercise Price, Options granted | 5.54 |
Weighted Avg. Exercise Price, Options exercised | 3.68 |
Weighted Avg. Exercise Price, Options cancelled/forfeit | 6.46 |
Weighted Avg. Exercise Price, Outstanding, Ending balance | 7.04 |
Weighted Avg. Exercise Price, Exercisable Ending Balance | 6.36 |
Weighted Avg. Exercise Price, Vested and expected to vest - end of period | $ 7.01 |
Weighted Avg. Remaining Contractual Life, Options outstanding | 5 years 7 months 24 days |
Weighted Avg. Remaining Contractual Life, Options exercisable | 5 years 9 months 15 days |
Weighted Avg. Remaining Contractual Life, Options vested and expected to vest | 5 years 8 months 1 day |
Aggregate Intrinsic Value, Options outstanding | $ | $ 196,275 |
Aggregate Intrinsic Value, Options exercisable | $ | 196,250 |
Aggregate Intrinsic Value, Options vested and expected to vest | $ | $ 196,273 |
Stockholders' Equity (Deficit43
Stockholders' Equity (Deficit) and Stock-Based Compensation - Schedule of Fair Value Assumption (Details) | 3 Months Ended |
Mar. 31, 2016$ / shares | |
Options Granted To Employees [Member] | |
Weighted-average fair value of options granted | $ 4.41 |
Expected terms (in years) | 6 years 1 month 10 days |
Expected volatility, minimum | 101.00% |
Expected volatility, maximum | 102.00% |
Risk-free interest rate, minimum | 1.52% |
Risk-free interest rate, maximum | 1.70% |
Dividend yield | |
Options Granted To Consultants [Member] | |
Weighted-average fair value of options granted | $ 4.37 |
Expected terms (in years) | 10 years |
Expected volatility | 104.00% |
Risk-free interest rate | 1.14% |
Dividend yield |
Stockholders' Equity (Deficit44
Stockholders' Equity (Deficit) and Stock-Based Compensation - Schedule of Shares Outstanding and Exercisable (Details) | 3 Months Ended |
Mar. 31, 2016$ / sharesshares | |
Number of Options Outstanding | shares | 1,543,563 |
Weighted Average Remaining Contractual Life in Years | 5 years 7 months 24 days |
Weighted Average Exercise Price | $ 7.04 |
Number Exercisable | shares | 700,669 |
Weighted Average Exercisable Exercise Price | $ 6.36 |
Range One [Member] | |
Range of Exercise Prices, minimum | $ 2.40 |
Number of Options Outstanding | shares | 125,000 |
Weighted Average Remaining Contractual Life in Years | 5 years 9 months 26 days |
Weighted Average Exercise Price | $ 2.40 |
Number Exercisable | shares | 125,000 |
Weighted Average Exercisable Exercise Price | $ 2.40 |
Range Two [Member] | |
Range of Exercise Prices, minimum | 3.96 |
Range of Exercise Prices, maximum | $ 4.50 |
Number of Options Outstanding | shares | 194,623 |
Weighted Average Remaining Contractual Life in Years | 4 years 2 months 9 days |
Weighted Average Exercise Price | $ 4.31 |
Number Exercisable | shares | 156,503 |
Weighted Average Exercisable Exercise Price | $ 4.36 |
Range Three [Member] | |
Range of Exercise Prices, minimum | 5.49 |
Range of Exercise Prices, maximum | $ 7.99 |
Number of Options Outstanding | shares | 970,353 |
Weighted Average Remaining Contractual Life in Years | 5 years 9 months 29 days |
Weighted Average Exercise Price | $ 7.53 |
Number Exercisable | shares | 199,302 |
Weighted Average Exercisable Exercise Price | $ 6.72 |
Range Four [Member] | |
Range of Exercise Prices, minimum | 8.06 |
Range of Exercise Prices, maximum | $ 8.99 |
Number of Options Outstanding | shares | 248,557 |
Weighted Average Remaining Contractual Life in Years | 6 years 26 days |
Weighted Average Exercise Price | $ 8.90 |
Number Exercisable | shares | 214,834 |
Weighted Average Exercisable Exercise Price | $ 8.93 |
Range Five [Member] | |
Range of Exercise Prices, minimum | $ 42.80 |
Number of Options Outstanding | shares | 5,030 |
Weighted Average Remaining Contractual Life in Years | 4 years 4 months 13 days |
Weighted Average Exercise Price | $ 42.80 |
Number Exercisable | shares | 5,030 |
Weighted Average Exercisable Exercise Price | $ 42.80 |
Stockholders' Equity (Deficit45
Stockholders' Equity (Deficit) and Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] | 3 Months Ended |
Mar. 31, 2016$ / sharesshares | |
Number of RSUs unvested, Outstanding, Beginning balance | shares | 1,487,961 |
Number of RSUs vested | shares | (11,893) |
Number of RSUs unvested, Outstanding, Ending balance | shares | 1,476,068 |
Weighted Average Grant Date Fair Value, Beginning balance | $ / shares | $ 3.18 |
Weighted Average Grant Date Fair Value, RSUs vested | $ / shares | 7.93 |
Weighted Average Grant Date Fair Value, Ending balance | $ / shares | $ 3.19 |
Stockholders' Equity (Deficit46
Stockholders' Equity (Deficit) and Stock-Based Compensation - Schedule of Warrants Activity (Details) - Warrant [Member] | 3 Months Ended |
Mar. 31, 2016$ / sharesshares | |
Number of shares, Outstanding, Beginning balance | shares | 240,688 |
Number of Shares Subject to Warrants Outstanding, Granted | shares | |
Number of Shares Subject to Warrants Outstanding, Exercised | shares | |
Number of Shares Subject to Warrants Outstanding, Expired/forfeited | shares | |
Number of shares, Outstanding, Ending balance | shares | 240,688 |
Weighted average remaining contractual life of the outstanding warrants in years | 5 years 8 months 27 days |
Weighted Avg. Exercise Price, Outstanding, Beginning balance | $ / shares | $ 7.41 |
Weighted Avg. Exercise Price, Granted | $ / shares | |
Weighted Avg. Exercise Price, Exercised | $ / shares | |
Weighted Avg. Exercise Price, Expired/forfeited | $ / shares | |
Weighted Avg. Exercise Price, Outstanding, Ending balance | $ / shares | $ 5.20 |
Stockholders' Equity (Deficit47
Stockholders' Equity (Deficit) and Stock-Based Compensation - Schedule of Warrants Outstanding and Warrants Exercisable (Details) - $ / shares | Mar. 16, 2016 | Mar. 31, 2016 |
Exercise Price | $ 3.60 | |
Expiration Date | May 11, 2025 | |
Warrant [Member] | ||
Warrants Outstanding | 240,688 | |
Exercise Price | $ 5.20 | |
Warrants Exercisable | 240,688 | |
Lender Warrants [Member] | ||
Issue Date | May 11, 2015 | |
Warrants Outstanding | 125,000 | |
Exercise Price | $ 3.60 | |
Warrants Exercisable | 125,000 | |
Expiration Date | May 11, 2025 | |
Underwriter Warrants [Member] | ||
Issue Date | Feb. 7, 2013 | |
Warrants Outstanding | 55,688 | |
Exercise Price | $ 5.25 | |
Warrants Exercisable | 55,688 | |
Expiration Date | Feb. 7, 2018 | |
Warrants Issued To Investor Relations Consultant [Member] | ||
Issue Date | Jul. 19, 2013 | |
Warrants Outstanding | 60,000 | |
Exercise Price | $ 8.50 | |
Warrants Exercisable | 60,000 | |
Expiration Date | Jul. 19, 2018 |
Stockholders' Equity (Deficit48
Stockholders' Equity (Deficit) and Stock-Based Compensation - Schedule of Stock Based Compensation Granted to Employees Directors Consultants (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2016 | Mar. 31, 2015 | |
Stock based compensation related to equity instruments granted to related parties | $ 1,064 | $ 658 |
Employees [Member] | Selling And Marketing [Member] | ||
Stock based compensation related to equity instruments granted to related parties | 120 | 68 |
Employees [Member] | General And Administrative [Member] | ||
Stock based compensation related to equity instruments granted to related parties | 885 | 521 |
Directors [Member] | General And Administrative [Member] | ||
Stock based compensation related to equity instruments granted to related parties | $ 59 | 45 |
Consultants [Member] | Selling And Marketing [Member] | ||
Stock based compensation related to equity instruments granted to related parties | $ 24 |
Derivative Instruments (Details
Derivative Instruments (Details Narrative) | Mar. 16, 2016$ / shares |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Debt conversion price per share | $ 5.90 |
Warrants exercise price per share | $ 3.60 |
Warrants expiration date | May 11, 2025 |
Convertible note matures date | May 11, 2022 |
Derivative Instruments - Schedu
Derivative Instruments - Schedule of Derivative Liabilities at Fair Value (Details) | 3 Months Ended |
Mar. 31, 2016 | |
Dividend yield | |
Minimum [Member] | |
Expected volatility | 103.00% |
Risk-free interest rate | 1.22% |
Maximum [Member] | |
Expected volatility | 111.00% |
Risk-free interest rate | 1.70% |
Derivative Instruments - Fair V
Derivative Instruments - Fair Value at Reconciliation of Measured Liabilities (Details) $ in Thousands | 3 Months Ended |
Mar. 31, 2016USD ($) | |
Warrant Derivative Liability [Member] | |
Balance Beginning | |
Modification of warrant and reclassification from equity to liabilities | $ 675 |
Change in fair value | (211) |
Reclassification from liabilities to equity upon closing of public equity offering | $ (464) |
Balance Ending | |
Embedded Conversion Feature Derivative Liability [Member] | |
Balance Beginning | |
Embedded conversion feature in Convertible Note issued | $ 2,322 |
Change in fair value | 324 |
Reclassification from liabilities to equity upon closing of public equity offering | $ (2,646) |
Balance Ending |
Commitments and Contingencies (
Commitments and Contingencies (Details Narrative) $ in Thousands | Apr. 02, 2014USD ($)shares | Mar. 31, 2016USD ($) | Mar. 31, 2015USD ($) | Mar. 31, 2016USD ($) | Dec. 31, 2015USD ($) |
Fair value of contingent acquisition obligation | $ 483 | $ 483 | $ 483 | ||
Asset purchase, license and commission expense | 361 | $ 2 | |||
Pharmacy Creations, LLC [Member] | |||||
Fair value of divided ratio | 18.5882 | ||||
Number of common stock shares issued for maximum exceeds from revenue | shares | 215,190 | ||||
Pharmacy Creations, LLC [Member] | Minimum [Member] | |||||
Revenue | 3,500 | ||||
Number of common stock shares issued for exceeds revenue value | $ 3,500,000 | ||||
Pharmacy Creations, LLC [Member] | Maximum [Member] | |||||
Revenue | 7,500 | ||||
Urigen Pharmaceuticals, Inc. [Member] | April 2016 [Member] | License Agreement [Member] | |||||
Unpaid royalties | $ 698 | $ 698 |
Segment Information and Conce53
Segment Information and Concentrations (Details Narrative) | 3 Months Ended | |
Mar. 31, 2016 | Mar. 31, 2015 | |
Segment Reporting [Abstract] | ||
Maximum percentage of sales derived from single customer | 10.00% | 10.00% |
Percentage of drug and chemical purchases from three main suppliers | 63.00% | 67.00% |
Sebsequent Events (Details Narr
Sebsequent Events (Details Narrative) - shares | 1 Months Ended | 3 Months Ended | |
May. 31, 2016 | Mar. 31, 2016 | Mar. 31, 2015 | |
Restricted Stock Units (RSUs) [Member] | |||
Number of shares vested during the period | 59,197 | 23,665 | |
Subsequent Event [Member] | Mark L. Baum [Member] | |||
Number of common stock shares issued for services | 200,000 | ||
Subsequent Event [Member] | Mark L. Baum [Member] | Restricted Stock Units (RSUs) [Member] | |||
Number of shares vested during the period | 200,000 |